Japanese Renal Cancer Imaging Trial Meets Study Objectives
Telix announces the Company’s ZIRDAC-JP study of its renal cancer imaging product demonstrates safety and tolerability in Japanese…
Read moreNews & Views
Launch of the International NOBLE Registry of Telix’s SPECT-Based Prostate Cancer Imaging Agent
Telix announces the launch of the international NOBLE Registry of Telix’s ‘rest of world’ prostate cancer imaging agent and the dosing of the first…
Read more
Australian TGA Accepts Telix’s Prostate Cancer Imaging Product Submission and Commences Priority Evaluation Process
Telix announces the Australian Therapeutic Goods Administration has accepted its prostate cancer imaging product submission and commenced the priority evaluation…
Read more
Telix Pharmaceuticals Limited – Notice of Annual General Meeting 2021
Telix Pharmaceuticals provides notice of The Annual General Meeting of Shareholders on Wednesday 12 May…
Read more
Telix Pharmaceuticals and Grand River Aseptic Manufacturing Complete Agreement for Commercial Manufacturing of Illuccix®
Telix announces it has completed an agreement with Grand River Aseptic Manufacturing to perform GMP manufacturing of Telix’s prostate cancer imaging…
Read more
Telix Appoints Darren Patti, Chief Operating Officer, Telix Pharmaceuticals (US) Inc.
News,
Telix is delighted to announce the appointment of Darren Patti as Chief Operating Officer, Telix Pharmaceuticals US (Inc). Darren brings with him over 15 years’ experience in radiopharmacy network management and…
Read more
Telix Pharmaceuticals and ITM Complete Global Agreements for Lutetium-177 Radioisotope Supply
Telix announces it has extended its non-exclusive global clinical and commercial supply agreements with Garching-based ITM…
Read more
Telix Appoints Sébastien Linard as General Manager, Telix European Manufacturing Facility
News,
Telix is delighted to announce the appointment of Sébastien Linard to the position of General Manager of Telix’s European Manufacturing in Seneffe,…
Read more
AUDIO LINK NOT INCLUDED – Telix Pharmaceuticals Releases Results for the Year Ended 31 December 2020 and 2020 Annual Report
Telix Pharmaceuticals Limited Releases Full-Year 2020 Results and 2020 Annual…
Read more
Telix and Kanazawa University Cleared to Commence Prostate Cancer Imaging Study in Japan
Telix Japan receives Clinical Trial Notification (CTN) clearance to commence a Phase I trial of its prostate cancer imaging product in…
Read more